4.5 Article

Sanitary safety of the 2021 French Intensive Care Society medical conference: a case/control study

Journal

ANNALS OF INTENSIVE CARE
Volume 12, Issue 1, Pages -

Publisher

SPRINGER
DOI: 10.1186/s13613-022-00986-x

Keywords

Mass gathering event; SARS-CoV-2; COVID-19; Transmission; Infectious disease; Prevention

Funding

  1. SRLF/FICS

Ask authors/readers for more resources

A prospective observational study of healthcare professionals attending a medical conference in France found that the probability of SARS-CoV-2 infection during the event was very low, indicating that in a low incidence period, there is no additional risk of infection associated with in-person mass gathering events.
Background In-person mass gathering events (MGE) are returning after a period of restrictions, yet few prospective scientific evaluations of their safety are available. Methods Prospective observational study, including both attendees of the French Intensive Care Society (FICS) annual meeting held in Paris between June the 9th and June the 11th, 2021 and matched controls (healthcare professionals who stayed in the ICU during the conference). SARS-CoV-2 lateral flow test was performed on day 7. Follow-up occurred until day 21. Results Out of the 1824 healthcare professionals attending the congress (all of which fulfilled legal requirements: 7 days or more following a second dose of vaccine or a negative PCR test performed within less than 72 h), 520 (28.5%) agreed to participate. Follow-up data were received for 216 (41.5%) out of the 520 included attendees, and for 191 matched controls. No positive SARS-CoV-2 lateral flow test was reported in the attendees or in the matched controls. The probability of SARS-CoV-2 infection during the MGE was less than 1.7% in the attendees (95% confidence interval [0;1.7%]), less than 2% in the controls (95%CI [0;2%]) and the difference in probabilities of infection was less than 1.9% (95% CI [0;1.9%]). Conclusion During a low incidence period, in this population of congress attendees screened for SARS-CoV-2 by a lateral flow test at day 7, no positive cases could be documented, no concomitant infection occurred in the matched controls; suggesting no extra risk of infection during the MGE. Trial Registration: ClinicalTrial.gov, #NCT04918160.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available